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UPDATED INTERIM PREGNANCY GUIDANCE:  
ASYMPTOMATIC PREGNANT WOMEN WITH POSSIBLE ZIKA VIRUS EXPOSURE
Testing Recommendations and Interpretation of Results for Healthcare Providers
ASK PREGNANT 
WOMEN ABOUT
Travel to or residence in any areas with risk for Zika virus transmission before and during the current pregnancy1,2 
Possible sexual exposure before and during the current pregnancy • A diagnosis of laboratory-confirmed Zika virus infection before current pregnancy3 • Symptoms of 
Zika virus disease during current pregnancy (e.g., fever, rash, conjunctivitis, arthralgia)  • If symptoms are reported, refer to symptomatic algorithm.
Before testing, discuss testing limitations and potential risks of misinterpretations for test results.
WHOM to test?
Asymptomatic pregnant women with ongoing possible 
Zika virus exposure4
Asymptomatic pregnant women with recent possible Zika virus exposure, without ongoing exposure: 
Testing not routinely recommended, but should be considered. 
If considering testing, base decisions on patient preferences and values, clinical judgment, a balanced 
assessment of risks and expected outcomes, and jurisdiction’s recommendations
If testing is conducted, follow algorithm for symptomatic pregnant women using  
timeframe from last possible exposure. 
WHEN to test? Three times during pregnancy
5 
First test at initiation of prenatal care.
WHICH tests? Zika virus NAT (serum and urine)
RESULTS Positive Zika virus NAT6 Negative Zika virus NAT
INTERPRETATION
ACUTE ZIKA VIRUS INFECTION NO ZIKA VIRUS RNA DETECTED. ZIKA VIRUS INFECTION 
DURING PREGNANCY CANNOT BE RULED OUT.7
Abbreviations: IgM = immunoglobulin M; NAT = nucleic acid test; PRNT = plaque reduction neutralization test
1 Ask about type and duration of Zika virus exposure before and during the current pregnancy.  Exposure 
prior to the current pregnancy may limit interpretation of Zika IgM antibody results; pretest counseling can 
help inform testing decisions. 
2 Possible Zika virus exposure includes travel to or residence in an area with risk for Zika virus transmission 
(https://wwwnc.cdc.gov/travel/page/zika-travel-information) during pregnancy or the periconceptional 
period (8 weeks before conception [6 weeks before the last menstrual period]), or sex without a condom 
during pregnancy or the periconceptional period, with a partner who traveled to, or resides in an area with 
risk for Zika virus transmission. 
3 Zika virus testing is not routinely recommended for pregnant women with a previous diagnosis of 
laboratory-confirmed Zika virus infection by either NAT or serology (positive/equivocal Zika virus or dengue 
virus IgM and Zika virus PRNT ≥10 and dengue virus PRNT <10 results).
4 Persons with ongoing possible exposure include those who reside in or frequently travel (e.g., daily or 
weekly) to an area with risk for Zika virus transmission. 
5 The interval for Zika virus NAT testing during pregnancy is unknown. Preliminary data suggest that NAT 
might remain positive for several weeks after infection in some pregnant women. For women without a 
prior laboratory-confirmed diagnosis of Zika virus, NAT testing should be offered at the initiation of prenatal 
care, and if Zika virus RNA is not detected on clinical specimens, two additional tests should be offered 
during the course of the pregnancy coinciding with prenatal visits. The proportion of fetuses and infants 
with Zika virus–associated birth defects is highest among women with first and early second trimester 
infections; therefore, conducting all NAT testing during the first and second trimesters might be considered 
to help identify infections early in pregnancy. However, adverse outcomes have been associated with 
infection diagnosed in the third trimester; therefore, testing every trimester might be considered.
6 Despite the high specificity of NAT, false positive NAT results have been reported. If both serum and urine 
specimens are NAT positive, interpretation should be acute Zika virus infection. If NAT is only positive 
on serum or urine, testing should be repeated on the original NAT-positive specimen. If repeat NAT is 
positive, results should be interpreted as evidence of acute Zika virus infection. If repeat NAT testing 
is negative, results are indeterminate and healthcare providers should perform IgM antibody testing on a 
specimen collected ≥2 weeks after the initial specimen collection. For laboratory interpretation, see Table 1.
7  A negative Zika virus NAT result does not exclude infection during pregnancy because it represents a single 
point in time. Zika virus RNA levels decline over time, and the duration of the presence of Zika virus RNA 
in serum and urine following infection vary among pregnant women. Despite Zika virus IgM test limitations 
(e.g., cross-reactivity with other flaviviruses and prolonged detection for months, presenting challenges in 
determining the timing of infection), which should be discussed as part of pretest counseling, patients may 
still choose to receive Zika virus IgM testing.
 Note: For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus 
infection is defined as a possible exposure or infection during the current pregnancy or periconceptional 
period.
https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w July 24, 2017CS267383-A
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TABLE 1. Interpretation of results1 of nucleic acid and antibody2,3 testing for suspected Zika virus infection — United States (including US territories), 2017




Zika virus IgM5 Zika virus PRNT Dengue virus PRNT Interpretation and recommendations
Positive Positive Any result Not indicated Not indicated Acute Zika virus infection
Negative Positive Positive Not indicated Not indicated Acute Zika virus infection
Negative Positive Negative Not indicated Not indicated
Suggests acute Zika virus infection 
Repeat testing on original urine specimen 
• If repeat NAT result is positive, interpret as evidence of acute Zika virus infection 
• If repeat NAT result is negative, repeat Zika virus IgM antibody testing on a serum specimen  
  collected ≥2 weeks after symptom onset or possible exposure or specimen collection date 
  − If repeat IgM antibody result is positive,6 interpret as evidence of acute Zika virus infection 
  − If repeat IgM antibody result is not positive, interpret as no evidence of Zika virus infection
Positive
Negative or  
not performed
Positive Not indicated Not indicated Acute Zika virus infection
Positive
Negative or  
not performed
Negative Not indicated Not indicated
Suggests acute Zika virus infection 
Repeat testing on original serum specimen 
• If repeat NAT result is positive, interpret as evidence of acute Zika virus infection 
• If repeat NAT result is negative, repeat Zika virus IgM antibody testing on a serum specimen  
  collected ≥2 weeks after symptom onset or possible exposure or specimen collection date 
  − If repeat IgM antibody result is positive,6 interpret as evidence of acute Zika virus infection 
  − If repeat IgM antibody result is not positive, interpret as no evidence of Zika virus infection
Negative





Zika virus infection; timing of infection cannot be determined. 
•  For persons without prior Zika virus exposure, a positive IgM result represents recent Zika  
virus infection
Negative





Flavivirus infection; specific virus cannot be identified; timing of infection cannot  
be determined 
•  For persons without prior Zika virus exposure, a positive IgM result represents recent unspecified 
flavivirus infection
Negative




<10 Any result No evidence of Zika virus infection
For areas where PRNT is not recommended3
Negative
Negative or  
not performed
Positive for Zika virus 
AND negative for 
dengue virus
Not performed because PRNT is not recommended Presumptive Zika virus infection; timing of infection cannot be determined8
Negative
Negative or  
not performed
Positive for Zika virus 
AND positive for 
dengue virus
Not performed because PRNT is not recommended
Presumptive flavivirus infection; specific virus cannot be identified;  
timing of infection cannot be determined8
Negative
Negative or  
not performed
Equivocal (either or  
both assays)
Not performed because PRNT is not recommended
Insufficient information for interpretation 
• Consider repeat testing
Negative
Negative or  
not performed
Negative on both 
assays
Not performed because PRNT is not recommended No laboratory evidence of Zika virus infection
Abbreviations: IgM = immunoglobulin M; NAT = nucleic acid test; PRNT = plaque reduction neutralization test.
1 Final interpretations of results of Zika virus tests should be performed after all testing is complete.
2 Serology test results that indicate flavivirus infection should be interpreted in the context of circulating flaviviruses.
3 Currently, PRNT confirmation is not routinely recommended for persons living in Puerto Rico.
4 Serum must be submitted for all persons tested for Zika virus infection; a urine specimen for Zika virus NAT testing should always be submitted concurrently  
with a serum specimen.
5 Dengue virus IgM antibody testing is recommended for symptomatic pregnant women, as well as for asymptomatic pregnant women residing in areas where PRNT 
confirmation is not recommended. For laboratory interpretation in the presence of dengue virus IgM results, refer to https://www.cdc.gov/dengue/clinicallab/
laboratory.html.      
6 Positive results include “positive,” “presumptive Zika virus positive,” or “possible Zika virus positive.” These are examples of assay interpretations that might 
accompany test results; positive serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific 
assay performed. Information on each assay can be found at https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika under the 
“Labeling” for the specific assay.
7 Non-negative results include “positive,” “equivocal,” “presumptive positive,” or “possible positive.” These are examples of assay interpretations that might 
accompany test results; nonnegative serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the 
specific assay performed. Information on each assay can be found at https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika  
under “Labeling” for the specific assay.
8 Zika virus IgM positive result is reported as “presumptive positive or flavivirus infection” to denote the need to perform confirmatory PRNT titers against Zika virus, 
dengue virus, and other flaviviruses to which the person might have been exposed to resolve potential false-positive results that might have been caused by cross-
reactivity or nonspecific reactivity. In addition, ambiguous test results (e.g., inconclusive, equivocal, and indeterminate) that are not resolved by retesting also should 
have PRNT titers performed to rule out a false-positive result. However, PRNT confirmation is currently not routinely recommended for persons living in Puerto Rico.
